|
|
| (One intermediate revision by the same user not shown) |
| Line 1: |
Line 1: |
| − | An intergal practice of the European Commission's pharmaceutical unit is to ensure a good quality of medicinal products for paedriatic use. In response to the incidence of inadequate medicines for children in Europe, the European Commission implemented a proposal on the 29th September 2004. Additionally this legislation seeks to promote the development of paediatric medicines, whereby at the national scale of EU member states have a role to play in providing national incentives for the research and development of such pharmaceuticals. <ref> Regulation on medicines for children http://ec.europa.eu/enterprise/pharmaceuticals/paediatrics/docs/paeds_qa_october_28.pdf Accessed 1/03/08 </ref>
| + | |
